← All Integra Lifesciences Holdings CORP filings

Integra Lifesciences Holdings CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
IART
Integra Lifesciences Holdings CORP
10-K: Integra LifeSciences Reports $516.5M Loss Amid Quality Issues & Tariffs
Integra LifeSciences reported a significant net loss of $516.5 million for 2025, primarily due to a $511.4 million goodwill impairment charge, alongside ongoing quality system challenges and increased tariff costs.
NASDAQ
IART
Integra Lifesciences Holdings CORP
10-K: Integra LifeSciences Reports Mixed 2024 Results Amidst Acquisition and Regulatory Challenges
Integra LifeSciences' 2024 results reflect revenue growth driven by the Acclarent acquisition, offset by quality and operational issues, resulting in a net loss for the year.
NASDAQ
IART
Integra Lifesciences Holdings CORP
10-K: Integra LifeSciences Holdings Corporation 10-K Filing: Detailed Analysis of Operations, Strategy, and Risk Factors
Integra LifeSciences' 10-K filing provides a comprehensive overview of the company's business, financial performance, strategic initiatives, and potential risks for the fiscal year ended December 31, 2023.